+41 91 682 20 40 info@elixi-int.com


We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.



As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more



We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.



European Commission Approves Merck’s DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen for the Treatment of HIV-1 in Appropriate Patients

Delstrigo is an antiviral medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that…

read more

FDA approves Elzonris (tagraxofusp-erzs), first treatment for rare blood disease

The U.S. Food and Drug Administration has approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm…

read more

FDA approves Xospata ( gilteritinib) for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation

The U.S. Food and Drug Administration has approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed…

read more

FDA approves Firdapse (amifampridine), first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder

The U.S. Food and Drug Administration has approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in…

read more

FDA approves Vitrakvi (larotrectinib), an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor.

The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients…

read more

Alunbrig ( brigatinib) approved by EMA for a specific group of lung cancer patients

Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell…

read more

FDA approves Daurismo (glasdegib) new treatment for patients with acute myeloid leukemia

The U.S. Food and Drug Administration has approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC),…

read more

Fexinidazole, first oral-only medicine for the treatment of human African trypanosomiasis (HAT), recommended for approval.

EMA’s human medicines committee has adopted a positive opinion for Fexinidazole Winthrop (fexinidazole), the first oral-only medicine (tablets) for the…

read more

Takhzyro (lanadelumab), a new medicine for hereditary angioedema, a rare disease causing swelling beneath the skin

The European Medicines Agency has recommended granting a marketing authorisation for Takhzyro (lanadelumab), the first monoclonal antibody therapy for the…

read more

Xofluza (baloxavir marboxil), new drug appoved for the treatment of influenza

On October 24th, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza…

read more

Pfizer’s Talzenna ( talazoparib) approved for breast cancer.

On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor,…

read more

U.S. FDA approves Bayer’s Xarelto (rovaroxaban) for patients with coronary or peripheral artery disease

The U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), 2.5 mg twice daily, plus aspirin low dose once…

read more


ELIXI International SA

Piazza Boffalora 4
6830 Chiasso / Switzerland

Tel: +41 91 682 20 40

Your name (required)

Your e-mail (required)

Your message